Table 3. Univariate and multivariate Cox regression analyses for OS in patients with bladder cancer.
| Variables | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | ||
| Primary cohort | |||||
| Sex | 1.961 (0.607–6.335) | 0.261 | |||
| Age | 1.341 (0.733–2.454) | 0.341 | |||
| SII | 3.753 (1.889–7.458) | <0.0001 | 3.102 (1.277–7.531) | 0.012 | |
| T stage | 2.133 (1.624–2.800) | <0.0001 | 1.896 (1.335–2.691) | 0.001 | |
| N stage | 7.642 (4.034–14.476) | 0.001 | 3.045 (1.333–6.957) | 0.008 | |
| M stage | 2.887 (1.135–7.345) | 0.026 | 3.052 (0.832–11.192) | 0.092 | |
| Tumor size | 2.266 (1.184–4.335) | 0.014 | 3.156 (1.269–7.849) | 0.013 | |
| Surgical type | 1.318 (0.934–1.859) | 0.116 | |||
| Blood transfusion | 1.124 (0.618–2.046) | 0.702 | |||
| Adjuvant chemotherapy | 1.115 (0.584–2.217) | 0.742 | |||
| Tumor margin | 2.472 (1.248–4.897) | 0.009 | 1.385 (1.156–2.951) | 0.039 | |
| Vessel invasion | 2.099 (1.119–3.940) | 0.021 | 1.419 (0.612–3.289) | 0.415 | |
| CAR | 3.666 (2.002–6.712) | 0.001 | 2.298 (1.120–4.716) | 0.023 | |
| NLR | 2.499 (1.265–4.937) | 0.008 | 1.676 (0.290–3.573) | 0.363 | |
| PLR | 1.957 (1.079–3.549) | 0.027 | 1.524 (0.222–2.236) | 0.14 | |
| BMI | 0.758 (0.407–1.410) | 0.381 | |||
| Diabetes | 0.869 (0.388–1.947) | 0.733 | |||
| Cardiovascular diseases | 0.808 (0.438–1.491) | 0.495 | |||
| Validation cohort | |||||
| Sex | 1.083 (0.324–3.623) | 0.897 | |||
| Age | 1.886 (0.827–4.302) | 0.132 | |||
| SII | 6.075 (2.308–15.988) | <0.0001 | 5.400 (1.262–23.113) | 0.023 | |
| T stage | 1.797 (1.283–2.516) | 0.001 | 1.733 (1.078–2.788) | 0.023 | |
| N stage | 2.773 (1.218–6.312) | 0.015 | 1.578 (0.228–2.655) | 0.307 | |
| M stage | 13.293 (1.553–113.789) | 0.018 | 2.629 (0.252–27.412) | 0.419 | |
| Tumor size | 2.444 (1.044–5.717) | 0.039 | 1.137 (0.386–3.346) | 0.815 | |
| Surgical type | 1.312 (0.830–2.075) | 0.245 | |||
| Blood transfusion | 1.927 (0.879–4.229) | 0.102 | |||
| Adjuvant chemotherapy | 1.538 (1.663–3.566) | 0.316 | |||
| Tumor margin | 2.753 (1.08–7.017) | 0.034 | 2.879 (1.073–7.727) | 0.036 | |
| Vessel invasion | 2.907 (1.312–6.439) | 0.009 | 1.386 (0.592–3.249) | 0.452 | |
| CAR | 5.381 (2.543–11.383) | 0.001 | 5.700 (2.438–13.327) | 0.001 | |
| NLR | 2.451 (1.088–5.524) | 0.031 | 1.658 (0.248–3.750) | 0.402 | |
| PLR | 2.405 (1.120–5.164) | 0.024 | 1.287 (0.516–3.209) | 0.588 | |
| BMI | 1.072 (0.523–2.199) | 0.85 | |||
| Diabetes | 1.556 (0.635–3.814) | 0.334 | |||
| Cardiovascular diseases | 1.169 (0.563–2.427) | 0.676 | |||
OS, overall survival; HR, hazard ratio; CI, confidence interval; SII, systemic immune-inflammation index; NLR, neutrophil-lymphocyte ratio; PLR, platelet-lymphocyte ratio; CAR, C-reactive protein/albumin ratio; BMI, body mass index.